NAC (N-Acetyl Cysteine): Evidence, Doses and the FDA Dispute

N-acetyl cysteine has had one of the stranger regulatory histories of any supplement on the market. It’s been used in emergency medicine for decades, studied in hundreds of clinical trials, and is on the World Health Organization’s list of essential medicines (as an antidote). Then, in 2020, the FDA said it couldn’t be sold as a dietary supplement at all.

The story of NAC tells you something important about how supplement regulation works — and about why this particular compound keeps showing up across such a wide range of health applications, from liver protection to lung function to longevity research.

This article covers what NAC actually does, what the evidence supports, where the limitations are, and how to think about dosing if you’re considering it.

What Is NAC?

NAC is the acetylated form of the amino acid L-cysteine. The acetyl group makes it more stable and better absorbed than plain cysteine. Once inside the body, NAC is converted to cysteine, which is then used to synthesize glutathione — the body’s primary endogenous antioxidant.

Glutathione is a tripeptide (glutamate + cysteine + glycine), and cysteine is the rate-limiting substrate. This means NAC supplementation directly increases cellular glutathione levels. That single mechanism explains most of NAC’s documented benefits.

Beyond glutathione synthesis, NAC has direct antioxidant activity of its own (the free thiol group scavenges reactive oxygen species), and it has mucolytic properties — it breaks disulfide bonds in mucus proteins, reducing viscosity. This last property is what put it on hospital formularies.

The FDA Controversy: What Actually Happened

In July 2020, the FDA sent warning letters to companies selling NAC ‘hangover’ products, arguing that NAC couldn’t legally be sold as a dietary supplement because it was “first approved as a new drug” in 1963 (as the mucolytic medication Mucomyst). Under the Dietary Supplement Health and Education Act, a compound that was first studied as a drug before being introduced as a supplement occupies a regulatory gray zone.

The supplement industry pushed back hard. The Council for Responsible Nutrition and others argued that NAC had a long history of use as a supplement independent of its drug applications, and that the FDA’s position was both legally uncertain and scientifically arbitrary.

In August 2022 the FDA issued final guidance saying it would exercise enforcement discretion — not act against NAC supplements that are otherwise lawful — while it considers a rule to permit NAC. As of 2026 that discretion stands and NAC remains widely available, but its legal status is unresolved.

This matters practically for two reasons: (1) the regulatory uncertainty is real, and (2) the controversy revealed that the FDA does not always draw these lines based on evidence of harm — NAC is one of the better-studied compounds in this space.

What the Research Actually Supports

Liver Protection (High-Quality Evidence)

The most robust human evidence for NAC involves liver protection. Intravenous NAC is the standard of care for acetaminophen (paracetamol) overdose — it restores glutathione depleted by acetaminophen’s toxic metabolite NAPQI, preventing acute liver failure. This is well-established medicine, not a supplement claim.

For non-emergency contexts, the evidence is more nuanced but still meaningful:

Non-alcoholic fatty liver disease (NAFLD): A small 2010 trial by Khoshbaten et al. (Hepatitis Monthly) found that NAC 600 mg twice daily for three months lowered ALT more than vitamin C in 30 NAFLD patients; it was small, short and not placebo-controlled.
Alcohol-related liver stress: Small studies suggest NAC may reduce markers of oxidative stress in alcohol-exposed individuals, consistent with its glutathione-restoring mechanism; no trial shows it protects the liver of people who drink.

Psychiatric Applications (Growing but Contested Evidence)

The psychiatric literature on NAC has grown substantially since Berk et al.’s 2008 RCT showing benefit in bipolar depression. The proposed mechanism: glutathione depletion and oxidative stress are increasingly implicated in several psychiatric conditions, and NAC appears to modulate both glutamate signaling and inflammatory pathways relevant to mood.

Key studies:

Bipolar depression: Berk et al. (2008, Biological Psychiatry) — 2,000 mg/day NAC over 24 weeks produced significant improvement in depression scores vs placebo in 75 patients. Benefits emerged slowly and were clearest at week 20; a later, larger trial by the same group (Berk et al. 2019) did not replicate the effect.
OCD: Small trials of NAC added to SSRIs in OCD are mixed: Afshar et al. (2012) and Paydary et al. (2016) reported benefit, Sarris et al. (2015) did not; a 2018 systematic review (Couto & Moreira) found a modest, inconsistent effect.
Addiction/craving: Several RCTs have examined NAC in substance use disorders, with the most consistent findings in cannabis dependence (Gray et al., 2012) and cocaine craving. The effect size is modest but notable given the mechanistic plausibility.

Important caveat: Most psychiatric NAC trials are small, and effect sizes are modest. This is not a replacement for established treatments — it’s a potential adjunct with a reasonably good safety profile.

Lung Function and Respiratory Health

The mucolytic mechanism is well-established. NAC reduces mucus viscosity by breaking disulfide bonds in mucoproteins. In clinical settings, this applies to:

Chronic obstructive pulmonary disease (COPD): A 2015 meta-analysis (Cazzola et al., European Respiratory Review) pooled 13 trials with 4,155 patients and found NAC reduced COPD exacerbations (RR 0.75, 95% CI 0.66–0.84), most clearly at 1,200 mg/day; the one-year HIACE trial (Tse et al., Chest 2013) tested that dose directly. The 600 mg/day dose used in most older studies did not reach statistical significance.
Chronic bronchitis: The mucolytic effect reduces cough frequency and mucus production in clinical trials.

Longevity and Aging Research (Preclinical — Early Stage)

The most speculative applications involve NAC’s role in longevity pathways. Glutathione depletion is a consistent feature of aging — older adults typically have lower intracellular glutathione than younger people — and restoring it has theoretical anti-aging appeal.

Several animal studies show life extension with NAC supplementation, and mechanistic work has identified interactions with mTOR, Nrf2 activation (via cysteine’s effect on Keap1), and mitochondrial function. However, robust human longevity data does not yet exist.

The NIA’s Interventions Testing Program has evaluated NAC in mice with mixed results. It remains speculative as a longevity intervention in humans.

What NAC Probably Does Not Do

Protect against COVID-19 or respiratory infections as a primary defense: Several researchers proposed this during 2020–2021 based on mechanistic arguments, but clinical trial results were inconsistent.
Significantly enhance athletic performance: A few studies have shown modest reductions in oxidative stress markers with NAC during high-intensity exercise, but effect sizes on performance outcomes are small and inconsistent.
Provide meaningful cognitive enhancement: Despite the mechanistic logic (oxidative stress is elevated in cognitive decline), clinical evidence for cognition in healthy adults is weak.

How NAC Compares to Direct Glutathione Supplementation

One obvious question: why not just take glutathione directly?

The problem is absorption. Oral glutathione is largely degraded in the GI tract before it can be absorbed intact. A 2015 trial by Richie et al. found that oral glutathione at 250 or 1,000 mg/day for 6 months modestly raised blood glutathione, but absorption is unreliable and variable.

NAC, by contrast, is absorbed as cysteine and drives intracellular glutathione synthesis directly. It’s a more reliable strategy for raising cellular glutathione than supplementing glutathione itself.

Liposomal glutathione formulations improve absorption somewhat, but remain more expensive and less well-studied than NAC.

Form	Absorption	Evidence Base	Cost
NAC	Good (oral)	Extensive (hundreds of trials)	Low
Oral glutathione	Poor, variable	Limited	Moderate
Liposomal glutathione	Better than standard	Limited RCTs	High
IV glutathione	Excellent	Clinical use only	High

Doses Used in the Studies

Doses in the trials varied by what was studied. COPD, bipolar disorder and OCD are medical conditions; in these trials NAC was given alongside prescribed treatment under supervision — talk to your clinician before adding it:

Application	Dose	Duration
General antioxidant / liver support	600 mg/day	Ongoing
COPD trials (alongside prescribed treatment)	1,200 mg/day	6–12 months
Psychiatric add-on trials (bipolar depression, OCD)	2,000 mg/day	12–24 weeks
Post-exercise oxidative stress	1,200 mg pre-exercise	Acute

Practical notes:

The 600 mg dose is the most commonly sold and studied for general health applications. For COPD and psychiatric applications, the evidence points to higher doses (1,200–2,000 mg).
Take with food to reduce GI side effects (nausea is the most common complaint at higher doses).
Consider taking NAC with glycine — the other rate-limiting substrate in glutathione synthesis. The NAC + glycine combination (dosed by body weight in the trials) has been studied as a more complete glutathione precursor strategy (Kumar et al. 2021 pilot, Clinical and Translational Medicine; Kumar et al. 2023 RCT, Journal of Gerontology: Series A).
In the psychiatric trials NAC was an add-on to prescribed treatment and any benefit took 8–20 weeks to appear; do not self-treat bipolar disorder or OCD with NAC, and never stop prescribed medication.

NAC + Glycine: The Underrated Combination

One of the more interesting developments in the NAC literature is the emerging evidence for NAC combined with glycine (GlyNAC). Glutathione synthesis requires three amino acids — glutamate (not typically limiting), cysteine (limiting, supplied by NAC), and glycine (also limiting in older adults).

A 2021 open-label pilot by Kumar et al. at Baylor College of Medicine (8 older adults, 24 weeks; a 24-person randomized trial followed in 2023) found that GlyNAC supplementation: - Raised red blood cell glutathione substantially (levels that were low at baseline normalized) - Reduced oxidative stress markers - Improved mitochondrial function markers - Improved muscle strength and gait speed

Sample size was small (8 older adults), and this is early-stage work, but the mechanistic argument is sound. If you’re supplementing NAC with longevity applications in mind, the evidence increasingly suggests that pairing it with glycine (which is also cheap and has its own evidence base for sleep quality) is the smarter strategy.

Safety and Contraindications

NAC has a good safety profile at standard doses:

Common side effects: Nausea, GI upset (more common at doses ≥ 1,200 mg). Taking with food reduces this significantly.

Rare side effects: Headache, rash. Anaphylaxis has been reported with IV NAC (more common than with oral forms) but is rare.

Drug interactions to consider: - Nitroglycerin / isosorbide dinitrate: NAC enhances vasodilatory effects — can cause severe hypotension and headache. Avoid combination. - Activated charcoal: May bind NAC if taken simultaneously (relevant only in overdose contexts). - Chemotherapy agents: Mixed data — some studies suggest NAC may reduce efficacy of certain platinum-based chemotherapy agents. Discuss with oncologist.

Specific populations: - Pregnancy: Insufficient data. The FDA drug form is used in pregnancy emergencies, but routine supplementation during pregnancy should be discussed with a physician. - Asthma: Inhaled NAC can cause bronchospasm. Oral forms are generally well-tolerated.

What Most Coverage Leaves Out

Five points that matter in practice:

The FDA controversy and what it actually means — knowing the regulatory background helps you evaluate the compound more accurately than just reading benefit lists.
The dose-response relationship for COPD — 600 mg doesn’t work for exacerbation prevention; 1,200 mg does. Most articles don’t note this.
Why direct glutathione supplementation is inferior — this is a mechanistic point that affects purchasing decisions.
The GlyNAC angle — this is where the most interesting current research is, and most popular coverage hasn’t caught up.
Psychiatric timelines — the benefit emergence at 8–20 weeks is clinically important and rarely emphasized.

Forms and Labels

NAC is inexpensive. Standard capsule/tablet products at 600 mg are widely available. For higher-dose applications, look for products with 600–1,000 mg per capsule to reduce pill burden.

Check for third-party testing (USP, NSF, or Informed Sport certification) if you’re using it for athletic applications where contamination matters.

Given the regulatory uncertainty in the US, availability may fluctuate. Products sold for “liver support” or “respiratory health” have generally remained on shelves through the FDA review period, but the situation is worth monitoring.

The Bottom Line

NAC is one of the better-studied compounds in the supplement category with clear applications in liver health, respiratory support, and specific psychiatric contexts as an adjunct. The regulatory controversy is real but has not been resolved in a way that restricts access.

The most clinically robust evidence is in COPD exacerbation prevention (at 1,200 mg/day) and acute liver protection. The psychiatric applications have the most interesting emerging evidence but require longer trials than most people expect.

For general health applications, 600 mg/day is a reasonable starting point with a low side effect burden. If you’re interested in the longevity angle, the GlyNAC combination is where the more compelling recent data points.

Sources

Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285-292.
Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451-461.
Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144(1):106-118.
Khoshbaten M, Aliasgarzadeh A, Masnadi K, et al. N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease. Hepat Mon. 2010;10(1):12-16.
Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder — a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468-475.
Berk M, Turner A, Malhi GS, et al. A randomised controlled trial of a mitochondrial agent, N-acetylcysteine, and a combination of nutraceuticals for bipolar depression. BMC Med. 2019;17:18.
Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169(8):805-812.
Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(6):797-803.
Sarris J, Oliver G, Camfield DA, et al. N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs. 2015;29(9):801-809.
Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016;41(2):214-219.
Couto JP, Moreira R. Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: a systematic review of the clinical evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:245-254.
Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-263.
Kumar P, Liu C, Hsu JW, et al. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: results of a pilot clinical trial. Clin Transl Med. 2021;11(3):e372.
Kumar P, Liu C, Suliburk J, et al. Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial. J Gerontol A Biol Sci Med Sci. 2023;78(1):75-89.
U.S. Food and Drug Administration. Policy Regarding N-acetyl-L-cysteine: Guidance for Industry (August 2022).

This article is for general education and is not medical advice. It does not replace a qualified clinician; talk to one before changing a supplement, medication or treatment, especially if you are pregnant, take medication or have a medical condition.